IGF2BP1 promotes gastric cancer progression by stabilizing HS6ST2 mRNA in an N6-methyladenosine-dependent manner

Figure 1 Insulin-like growth factor 2 mRNA-binding protein 1 is highly expressed in gastric cancer and correlates with lymph node metastasis and poor prognosis. A: Immunohistochemical analysis showing higher N6-methyladenosine levels in gastric cancer tissues with lymph node metastasis (LNM) compared with those without LNM (n = 36); B: Analysis of GSE17187 indicating upregulation of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in gastric cancer (GC) tissues with LNM; C: Kaplan-Meier survival analysis of The Cancer Genome Atlas-stomach adenocarcinoma showing that high IGF2BP1 expression is associated with shorter overall survival; D: The Cancer Genome Atlas-stomach adenocarcinoma analysis demonstrating poorer overall survival in patients with GC with LNM; E: Immunohistochemical analysis confirming elevated IGF2BP1 expression in GC tissues relative to paired adjacent non-tumor tissues; F and G: IGF2BP1 mRNA and protein expression levels across GC cell lines, with MGC803 and SGC-7901 showing high expression. Data are presented as mean ± SD. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. LN: Lymph node; m6A: N6-methyladenosine; IGF2BP: Insulin-like growth factor 2 mRNA-binding protein; TPM: Transcripts per million; HR: Hazard ratio; GAPDH: Gyceraldehyde-3-phosphate dehydrogenase.